Functional Constipation: What to Do When Lactulose Has Not Achieved Adequate Relief
In adults with functional constipation, osmotic laxatives such as lactulose syrup represent an early therapeutic step. When that step does not deliver sufficient symptom relief or an adequate responder rate, a next-line protocol is indicated.
The prior treatment step, lactulose syrup, targets global relief of constipation symptoms and a higher responder rate. This protocol applies when those goals have not been achieved and escalation is required.
This protocol employs prescription-grade agents used as a replacement for, or adjunct to, over-the-counter options. The selection criteria, sequencing, and dose adjustments for specific patient profiles are detailed in the full evidence-based regimen — only a portion of the approach is outlined here.
The aim is to increase the number of complete spontaneous bowel movements and total spontaneous bowel movements per week. In patients who respond, meaningful improvement can manifest within days of starting therapy.
- In adults with CIC who do not respond to OTC agents, the panel suggests the use of lubiprostone over management without lubiprostone (conditional recommendation, low certainty of evidence).
- In adults with CIC who do not respond to OTC agents, the panel recommends the use of linaclotide over management without linaclotide (strong recommendation, moderate certainty of evidence).
- In adults with CIC who do not respond to OTC agents, the panel recommends the use of plecanatide over management without plecanatide (strong recommendation, moderate certainty of evidence).
- In adults with CIC who do not respond to OTC agents, the panel recommends the use of prucalopride over management without prucalopride (strong recommendation, moderate certainty of evidence).
- The use of linaclotide leads to increases in the number of CSBMs per week (MD 1.37, 95% CI 1.07–1.95) and SBMs per week (MD 1.97, 95% CI 1.59–2.36), improves stool consistency (MD 1.25, 95% CI 1.1–1.39 higher), and increases the rates of global relief (RR 1.96, 95% CI 1.63–2.35).
- Among individuals who respond, these effects generally manifest within 2 days.